ライフサイエンスコーパス: confidence

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 extent of reduction of subjective retrieval confidence.

2 es can now be examined with a high degree of confidence.

3 ted agreement was determined to be 0.44 (95% confidence = 0.16-0.68, Fleiss' kappa).

4 The secondary aim was to gauge the confidence and experience of ophthalmologists in Scotlan

5 The association between confidence and fixations varied across individuals as a

6 gnals that combine reward value with sensory confidence and guide subsequent learning.

7 activities on three main areas: (a) trainee confidence and knowledge to make career decisions, (b) i

8 of decisional and postdecisional accounts of confidence and propose a computational model of confiden

9 Such high-confidence associations include NEGR1, CTC-467M3.3, TMEM

10 yses of splicing, and identified 13,149 high-confidence cassette exon events with variable incorporat

11 y and abstain from making assignments in low-confidence contexts.

12 hms require identification of a list of high confidence (core) reactions from transcriptomics, but pa

13 riptional effects yielded inferences of high confidence for effects on splicing even of mutations in

14 lues for one trait, and 28-81% provided high confidence for multiple traits concurrently.

15 s as manifested in self-beliefs-that is, the confidence gap-commands attention to reduce the gender p

16 3 genomic DNA, resulting in a set of 55 high-confidence gRNA cleavage sites identified by both method

17 hat r(e) could be reduced below one with 95% confidence if 86% of FGD flocks were vaccinated in the b

18 The use of IVC increases the degree of confidence in a novel radiologist, while in the expert i

19 The survey explored providers' confidence in counseling, explanation of VUSs, topics co

20 red two questions evaluating their degree of confidence in interpreting ultrasonographic images and h

21 tual uncertainty suggests a unified role for confidence in learning under different types of uncertai

22 Decision makers must have sufficient confidence in models if they are to influence their deci

23 Healthy volunteers reported their confidence in the accuracy of decisions they made or dec

24 Data pooling to increase the confidence in the discovered mutations, moves the discov

25 er multiple length scales resulted in higher confidence in the recovered fitting parameters.

26 ncer immunotherapy, which range from lack of confidence in translating pre-clinical findings to ident

27 fidence and propose a computational model of confidence in which metacognitive performance naturally

28 y encoded reward prediction errors graded by confidence, influencing subsequent choices.

29 isease [incidence rate ratio (IRR) 1.17; 95% confidence interval (CI) 0.76-1.63; P = 0.467], but ther

30 the relative risk (RR) of FTR was 0.84, (95% confidence interval (CI) 0.78-0.90) after implementation

31 than sleeve gastrectomy (SG; 64.5%; RR 0.92, confidence interval (CI) 0.86-0.99) and adjustable gastr

32 eferred to the ED [odds ratio (OR) 1.32, 95% confidence interval (CI) 1.09-1.60].

33 of product with any "high in" (from 51% [95% confidence interval (CI) 49-52] to 44% [95% CI 42-45]),

34 After adjustments, WLZ-O had 89 g (95% confidence interval (CI) 5; 172) lower FFM compared to M

35 We examine the bias, confidence interval (CI) coverage, and bias-variance tra

36 ng to estimate the hazard ratio (HR) and 95% confidence interval (CI) for the association of CRC diag

37 we found no group difference (d = 0.03 [95% confidence interval (CI), -0.20 to 0.26], z = 0.28, p =

38 the internal validation cohort of 0.76 [95% confidence interval (CI), 0.72 to 0.79] for AKI, 0.79 (9

39 drops [area under the curve (AUC), 0.93; 95% confidence interval (CI), 0.87-1.00].

40 clude tobacco use (odds ratio (OR), 2.0; 95% confidence interval (CI), 1.2-3.4, P = 0.009), coronary

41 ighest vs. lowest quartile of FLI),1.63; 95% confidence interval (CI), 1.23-2.16; P = 0.001 for trend

42 al tumor in 37 of 208 women [FNR, 17.8%; 95% confidence interval (CI), 12.8-23.7%].

43 h AD eyes in mild glaucoma (mean, 42.2% [95% confidence interval (CI), 41.2%-43.2%] and 46.5% [95% CI

44 e used to estimate hazard ratio (HR) and 95% confidence interval (CI).

45 3, and TT3 [absolute difference: - 0.62; 95% confidence interval (CI): - 0.12, - 0.01; p = 0.04; abso

46 th an increase of MI 6 h later by 3.27% [95% confidence interval (CI): 0.27, 6.37], 5.71% (95% CI: 1.

47 nation with 1, 2, and 3 doses were 0.53 (95% confidence interval (CI): 0.37, 0.76; VE = 47%), 0.45 (9

48 rols (mean difference (MD) = 0.59 units, 95% confidence interval (CI): 0.39, 0.80), lower physical ac

49 d survival [adjusted hazard ratio 0.61; (95% confidence interval (CI): 0.50-0.76)].

50 d with ALL risk (odds ratio (OR) = 0.85, 95% confidence interval (CI): 0.60, 1.21).

51 er (cc)] relative UFP exposure was 1.04 [95% confidence interval (CI): 1.02, 1.06].

52 ees of malnutrition, respectively: 2.02 [95% confidence interval (CI): 1.65 to 2.49] and 3.65 [95% CI

53 udy areas (overall incidence rates 12.5 [95% confidence interval (CI): 11.2, 14.1] and 871.1 [95% CI:

54 nd >39.0 years were associated with 22% (95% confidence interval (CI): 14, 30), 25% (95% CI: 17, 33),

55 OPF (10.7% vs 35.5%, P < 0.001; OR 0.20, 95% confidence interval 0.12-0.33).

56 e wound complications (Odds Ratio 0.400 [95% confidence interval 0.168, 0.954], p = 0.039).

57 ith: being male (hazard ratio (HR) 1.59 (95% confidence interval 1.53-1.65)); greater age and depriva

58 conservative group (mean difference 9.7, 95% confidence interval 1.7-17.7, P = 0.018), which approach

59 etween 60-80% long shifts was 15% lower (95% confidence interval 2% to 27%) than with all long shifts

60 ed with strain sharing (odds ratio 8.50; 95% confidence interval 2.2 - 33.4, P = 0.002).

61 idence interval 38.5-75.5) vs 33 months (95% confidence interval 20.3-45.7), P = 0.03].

62 ot confer a survival benefit [57 months (95% confidence interval 38.5-75.5) vs 33 months (95% confide

63 had ASN corresponding to at least 9.18% (95% confidence interval 4.29%-16.72%).

64 4-year cumulative probability being 9% (95% confidence interval 7%-12%).

65 otor scores at 4.5 years (beta = -0.095, 95% confidence interval = -0.184 to -0.005), with a standard

66 and SoC approaches was 26 of 34 (76.5%, 95% confidence interval = 58.8-89.3%) in <4 months, greater

67 their diagnoses for 72% of the patients (95% confidence interval = 60-85%); chance-adjusted agreement

68 justed incidence rate ratio [aIRR] 1.12, 95% confidence interval [95% CI] 1.11-1.13, p < 0.001, per d

69 ed risk of CKD (hazard ratio [HR], 1.51; 95% confidence interval [95% CI], 1.08 to 2.10), which was a

70 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P=0.02) as wel

71 rhosis (adjusted odds ratio [aOR], 2.67; 95% confidence interval [95% CI], 2.30 to 3.08), and ESKD (a

72 a 9.15-fold increase in the odds of AKI (95% confidence interval [95% CI], 3.64 to 22.93) and a 22.86

73 K6 5-12: adjusted odds ratio [AOR] 0.86, 95% confidence interval [95%CI] 0.82, 0.90; K6 >= 13: AOR 0.

74 The mean costs per patient were US $847 (95% confidence interval [CI] $776-927) for FLU+5FC, and US $

75 ndardised mean difference [SMD] = -0.82, 95% confidence interval [CI] -1.02 to -0.63) and active cont

76 These changes led to a -96.1 ml (95% confidence interval [CI] -144.2 to -48.0) reduction in v

77 (incidence rate = 0.28/person-year [PY], 95% confidence interval [CI] 0.22-0.35/PY).

78 , colorectal cancer incidence was 0.55% (95% confidence interval [CI] 0.40-0.75) with low-performing

79 y 24% (hazard ratio [HR] per year 0.976; 95% confidence interval [CI] 0.959-0.993).

80 neonates were heavier at birth (58.20 g, 95% confidence interval [CI] 10.10-106.31, p = 0.02) with in

81 e rates per 1000 person-years were 20.6 (95% confidence interval [CI] 19.6-21.6) among untreated pers

82 hallenge (adjusted odds ratio [OR] 3.81, 95% confidence interval [CI] 2.49 to 5.86) and added a signi

83 nd 696 young women (20-24 years), 31.7% (95% confidence interval [CI] 29.5-34.1), of whom were displa

84 4 to 8 (P = .004, odds ratio [OR] 31.3, 95% confidence interval [CI] 3.0 to 329) and cumulative RFI

85 nosis of melanoma (odds ratio [OR] 5.01; 95% Confidence Interval [CI] 3.50-7.61) and kidney cancer (O

86 ll, uBPA concentrations were 86% higher (95% confidence interval [CI] 42% to 143%, P < 0.001) at 2 d

87 sensitivity for buccal samples was 51% (95% Confidence Interval [CI] 42-60%).

88 st 4 weeks after IE diagnosis (HR 57.20, 95% confidence interval [CI] 45.58-71.78; P < .0001) and a m

89 nths of progression-free survival (PFS) (95% confidence interval [CI] 5-29, 49-69 versus 70-82 months

90 ce standard, CrAgSQ was 93.0% sensitive (95% confidence interval [CI] 80.9% to 98.5%) and 93.8% speci

91 f PCR-adjusted ACPR at Day 42 was 96.1% (95% confidence interval [CI] 91.4-98.2; Kaplan-Meier).

92 = 57%, adjusted odds ratio [aOR] = 1.91, 95% confidence interval [CI] = 0.40-9.01, p = 0.41).

93 CH (vs 0-3 days; odds ratio [OR] = 1.49, 95% confidence interval [CI] = 0.50-4.43), nor did they have

94 cantly lower for African-American (0.67; 95% confidence interval [CI] = 0.58 to 0.78) and Hispanic or

95 tal cholesterol (odds ratio [OR] = 0.92; 95% confidence interval [CI] = 0.85-0.99; p = 0.03) and LDL

96 e at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10-11.1, p = 0.03 and RR =

97 ly active lesions contain 64% more iron (95% confidence interval [CI] = 17-127%, p = 0.004) than immu

98 ncrease in WHR there was a 75% increase (95% confidence interval [CI] = 44-113%) in risk for large ar

99 creased from 0.00 after 5 years to 0.22 (95% confidence interval [CI], -0.01 to 0.67) after 30 years.

100 ents were: ME from RVO, -0.56 (774 eyes; 95% confidence interval [CI], -0.61 to -0.51; P < 0.001); DM

101 usted difference, 0.7 percentage points; 95% confidence interval [CI], -0.9 to 2.4) - a result that s

102 e placebo group was 2 percentage points (95% confidence interval [CI], -18 to 27) for the 20-mg dose,

103 lesterol level was a reduction of 39.7% (95% confidence interval [CI], -43.7 to -35.7) in the inclisi

104 tive NPS and saliva specimens was -3.61 (95% confidence interval [CI], -5.78 to -1.44; P = 0.002).

105 he crude mean VA change of +1.5 letters (95% confidence interval [CI], 0-3.1 letters) in the ranibizu

106 ried by world region, from 2.6% in Asia (95% confidence interval [CI], 0-5.9) to 10.5% in Australia (

107 r more VA gain was 0.49 events/eye-year (95% confidence interval [CI], 0.26-0.86 events/eye-year), wh

108 from baseline to month 24 was +0.36 mm (95% confidence interval [CI], 0.27-0.45 mm) for ranibizumab

109 subdistribution hazard ratio [sHR] 0.74; 95% confidence interval [CI], 0.40-1.34; P = 0.38) and death

110 of age vs. 66-70 years of age: OR, 0.49; 95% confidence interval [CI], 0.48-0.50), whereas women were

111 er 100 person-years; hazard ratio, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001).

112 this was not statistically significant (95% confidence interval [CI], 0.57-3.06; P = 0.51).

113 years of age showed a myopia OR of 0.65 (95% confidence interval [CI], 0.63-0.67; P < 10(-205)) and 0

114 0.9 per nanograms per milliliter of PSA; 95% confidence interval [CI], 0.8, 0.9; P < .001).

115 opioid injecting (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.92-0.99) and sharing (OR, 0.

116 rse OS and DFS (OS: hazard ratio [HR], 0.98; confidence interval [CI], 0.97-1.00; P = 0.013; DFS: HR,

117 cases from controls with AUCs of 0.992 (95% confidence interval [CI], 0.983 to 1.000) and 0.984 (95%

118 were age at LT (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.01-1.07), male gender (HR, 2

119 r tumor diameter (odds ratio [OR], 1.15, 95% confidence interval [CI], 1.03-1.30) and alpha-fetoprote

120 transformation (odds ratio [OR], 3.729; 95% confidence interval [CI], 1.099-12.649; P = 0.035).

121 tters) were least squares means of +1.1 (95% confidence interval [CI], 1.0;1.3), -1.3 (95%CI, -1.5;-1

122 acular atrophy (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.17-2.49; P = 0.006).

123 years (adjusted odds ratio [aOR], 1.75; 95% confidence interval [CI], 1.18, 2.60, P = .01), AA ident

124 th (age-adjusted odds ratio [aOR], 1.50; 95% confidence interval [CI], 1.19-1.88), preterm premature

125 1000 patient-days; relative risk, 1.53; 95% confidence interval [CI], 1.37 to 1.72; P<0.001).

126 early morning IOP increase of 4.3 mmHg (95% confidence interval [CI], 1.4-7.3; P = 0.005) and mean i

127 immunogenicity (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.60-2.25; P = 5.88 x 10(-13))

128 the average RNFL thickness was 2.5 mum (95% confidence interval [CI], 1.8-3.1 mum), 2.8 mum (95% CI,

129 both neovascular (hazard ratio, 11.036; 95% confidence interval [CI], 1.807-67.393) and total (hazar

130 dults was 1772 per 100 000 person-years (95% confidence interval [CI], 1754-1789) and 303 per 100 000

131 jects with TLs (hazard ratio [HR] = 8.5; 95% confidence interval [CI], 3.1-23; P < .001).

132 centage points (upper boundary of the 98.75% confidence interval [CI], 3.3), and that between the 20-

133 io [HR] for <50 vs >=500 cells/uL, 13.4; 95% confidence interval [CI], 3.5-51.0) and proportion of ti

134 Hepatitis C virus infection (OR, 15.84; 95% confidence interval [CI], 4.06-61.87; P < 0.001) was the

135 task had 11.2 times the odds of frailty (95% confidence interval [CI], 5.2-23.9), 2.6 times the odds

136 e percentage who had a response was 69% (95% confidence interval [CI], 55 to 81), and 1-year progress

137 caused an estimated 622,390 infections (95% confidence interval [CI], 579,125 to 665,655) among hosp

138 psy 1, mean %HCV-infected cells = 25.2% (95% confidence interval [CI], 7.4%-42.9%), correlating with

139 external validation cohorts were 83.5% (95% confidence interval [CI], 75.4-90.7%) and 91.9% (95% CI,

140 Overall survival was 83.3% (95% confidence interval [CI], 76.2-88.4) at 1 year posttrans

141 inal swabs and urine samples were 96.6% (95% confidence interval [CI], 88.5 to 99.1%) and 86.4% (95%

142 wing doxycycline-azithromycin was 95.4% (95% confidence interval [CI], 89.7-98.0) and doxycycline-mox

143 ge [IQR], 0.22 to 1.46 cp/ml) and a 14% (95% confidence interval [CI], 9% to 19%) decline in viral lo

144 pretreatment LI-RADS category was 0.40 (95% confidence interval [CI]: 0.15, 0.67; P < .01) and was l

145 om-effects meta-analyses and were 0.32% (95% confidence interval [CI]: 0.26% to 0.39% [corresponding

146 medical mistrust (odds ratio [OR]: 0.59; 95% confidence interval [CI]: 0.39, 0.91), experienced discr

147 CV readmission (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.62 to 0.94, and HR: 0.74; 95

148 AUC) for the image-based model was 0.73 (95% confidence interval [CI]: 0.71, 0.74).

149 s placebo drug (hazard ratio [HR]: 0.87; 95% confidence interval [CI]: 0.76 to 0.98; p = 0.028).

150 BL arm adjusted odds ratio [AOR] = 1.00, 95% confidence interval [CI]: 0.77-1.30, p = 0.973; women's

151 rating characteristic curve [AUC], 0.97; 95% confidence interval [CI]: 0.94, 1.00) and excellent inte

152 vs 23.3 months; hazard ratio [HR], 1.87; 95% confidence interval [CI]: 1.01, 3.5; P = .04) and advanc

153 rasugrel group (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.04 to 1.90).

154 and maintenance (odds ratio [OR]: 1.26; 95% confidence interval [CI]: 1.12-1.41; Q < 0.001), and gre

155 ymphadenopathy (relative risk [RR]: 1.7; 95% confidence interval [CI]: 1.2, 2.4; P = .002) and osseou

156 mia (univariate hazard ratio [HR]: 2.70; 95% confidence interval [CI]: 1.27 to 5.77; p = 0.01 vs. no/

157 years; adjusted hazard ratio [HR]: 2.35; 95% confidence interval [CI]: 2.0 to 2.76; p < 0.001) and de

158 pre-term delivery (<37 weeks) was 2.47 (95% confidence interval [CI]: 2.16 to 2.82), and further str

159 of outcomes were as follows: HF: 3.18% (95% confidence interval [CI]: 2.83% to 3.57%) for sarcoidosi

160 nt yielded a pooled upgrade rate of 29% (95% confidence interval [CI]: 26%, 32%) for surgically excis

161 was longer in the BEV group (3.7 months; 95% confidence interval [CI]: 3.0, 4.2) compared with the no

162 D, and cerebrovascular disease was 40.8 (95% confidence interval [CI]: 40.3 to 41.3), 68.9 (95% CI: 6

163 Immune response of mOPV2 was 53.6% (95% confidence interval [CI]: 44.9%-62.1%) and 60.6% (95% CI

164 CIs were found in 61 of 105 skiers (58%; 95% confidence interval [CI]: 48.5%, 67.2%) compared with 28

165 p detection than conventional CT (58.8%; 95% confidence interval [CI]: 49.7%, 67.3%; 564 of 960 polyp

166 tor of matrix metalloproteinase 1 by 8% (95% confidence interval [CI]: 6% to 10%; p < 0.001), soluble

167 ghest-performing (baseline) SSD was 81% (95% confidence interval [CI]: 80%, 82%; 190 of 234) and PPV

168 ting a fracture of this model was 93.7% (95% confidence interval [CI]: 90.8%, 96.5%), with a sensitiv

169 n (>15%) with 98% accuracy (202 of 207) (95% confidence interval [CI]: 95%, 99%).

170 e overall mean IOP change was -0.5 mmHg (95% confidence interval CI, -0.6 to -0.3 mmHg) at 12 months

171 The corresponding 95% confidence interval coverage rate ranged from 46.4% to 6

172 er concentrations in rats and within the 95% confidence interval of observed plasma silver concentrat

173 The lower limit of the 2-sided 90% confidence interval was -1.724 letters, which is within

174 ority declared if the lower bound of the 95% confidence interval was greater than -12%.

175 .8% versus 4.7% [odds ratio {OR} = 5.05; 95% confidence interval {CI} = 3.01 to 8.46]; for males, 16.

176 eracillin/tazobactam (difference, -5.3% [95% confidence interval {CI}, -11.9% to 1.2%]), and favorabl

177 ormalized abundance (4-month mean, 0.71 [95% confidence interval {CI}, .2-1.2] and 6-month mean, 0.85

178 us ranibizumab (hazard ratio [HR], 0.96 [95% confidence interval {CI}, 0.74-1.25]; HR, 1.04 [95% CI,

179 hrHPV (adjusted odds ratio [aOR], 6.08 [95% confidence interval {CI}, 1.27-29.18], P = .02) and with

180 nt (multivariable odds ratio [mOR], 2.9 [95% confidence interval {CI}, 1.3-6.4]; P = .008), African o

181 24- and 6-fold higher (risk ratios, 24 [95% confidence interval {CI}, 10.8-62.3] and 6 [95% CI 1.5-2

182 ed 40 mg (clearance half-life 5.5 hours [95% confidence interval {CI}, 5.2-6.0 hours] vs 6.4 hours [9

183 tter 5-year OS (hazard ratio [HR], 0.53 [95% confidence interval {CI}: 0.29, 0.94]; HR, 0.40 [95% CI:

184 odds ratio, 2.0 per one-grade increase [95% confidence interval {CI}: 1.6, 2.4]; P < .001), carotid

185 000 enrollees per year for Medicare: 91 [95% confidence interval {CI}: 34, 148]; commercially insured

186 of OSA showed an adjusted hazard ratio (95% confidence interval) of 1.54 (1.06-2.24; P value = 0.02)

187 The adjusted proportion (95% confidence interval) of LTs paid by Medicaid among restr

188 A proportion metaanalysis (with 95% confidence interval) was performed using the random-effe

189 regression (odds ratio or hazard ratio, 95% confidence interval), diabetes (1.9, 1.4-3.0), pannicule

190 number compared to non-WASH arms, -0.07 [95% confidence interval, -.14 to -.02]), but had no statisti

191 rease in the lung volume of exhaled air (95% confidence interval, -0.17 to -0.07; P = 6.62 x 10(-8))

192 ifference between proportions was 0.87% (95% confidence interval, -0.84% to 2.59%).

193 18 and 30 (adjusted relative risk, 0.30 [95% confidence interval, .12-.74]; P = .010).

194 ficant trend (adjusted odds ratio, 1.44; 95% confidence interval, .81-2.56).

195 and year of admission (odds ratio, 0.97; 95% confidence interval, .85-1.12; P = .71).

196 6B plasma detection (hazard ratio, 0.40; 95% confidence interval, 0.20-0.80).

197 r-negative patients (hazard ratio, 0.49; 95% confidence interval, 0.280-0.86; P = .0096).

198 ment of bronchiectasis (difference, 0.9; 95% confidence interval, 0.3-1.6; P = 0.003) and Aspergillus

199 kidney from donors >=80 years was 0.54 (95% confidence interval, 0.38-0.77; P < 0.0001).

200 3 to 8 years (adjusted odds ratio, 0.73; 95% confidence interval, 0.57-0.93).

201 different (adjusted hazard ratio, 1.07; 95% confidence interval, 0.68-1.68; P = 0.76).

202 48-72 hours (adjusted odds ratio, 0.87; 95% confidence interval, 0.79-0.94).

203 94 children [26%]; relative risk, 1.03; 95% confidence interval, 0.81 to 1.32; P = 0.80).

204 ed with standard care (odds ratio, 2.07; 95% confidence interval, 0.98-4.40; P = 0.058).

205 illus with trapped air (difference, 3.2; 95% confidence interval, 1.0-5.4; P = 0.004).

206 stational-age infants (odds ratio, 1.15; 95% confidence interval, 1.06, 1.24); conversely, there was

207 er risk of amputation (risk ratio, 1.80; 95% confidence interval, 1.07-3.01), as was the presence of

208 ant outcomes (marginal relative risk and 95% confidence interval, 1.161.501.95).

209 -30.6; MLH1: P = 0.04; odds ratio, 25.4; 95% confidence interval, 1.2-143; SMARCE1: P = 0.001; odds r

210 , and paternal origin (adjusted HR, 3.2; 95% confidence interval, 1.3 to 7.7).

211 (>=358 pg/mL) had an OR for VTE of 2.05 (95% confidence interval, 1.37-3.08) compared with those with

212 was seen for diabetes (rate ratio, 1.55; 95% confidence interval, 1.48-1.61).

213 trols (PALB2: P = 0.02; odds ratio, 8.9; 95% confidence interval, 1.5-30.6; MLH1: P = 0.04; odds rati

214 for deprivation (adjusted odds ratio 4.0 95% confidence interval, 1.7-10.6).

215 d 42% in the LBT arm (odds ratio, 28.72; 95% confidence interval, 10.27-80.31).

216 /330 (53.6%; percentage decrease, 26.5%; 95% confidence interval, 18.7-34.1) with no change in the ca

217 1 kPa or more (adjusted odds ratio, 4.8; 95% confidence interval, 2.0-11.8).

218 ith increased 30-day mortality (OR, 8.4 [95% confidence interval, 2.23-31.7]).

219 IPD cases, we observed a 35.3% decrease (95% confidence interval, 29.2%-41.8%]) and the median age sh

220 had higher incidences of diabetes (4.74 [95% confidence interval, 3.09-7.27] vs 0.87 [.42-1.83] per 1

221 Three-year OS was 55.5% (95% confidence interval, 40.8-68.0).

222 3; SMARCE1: P = 0.001; odds ratio, 2047; 95% confidence interval, 52-4.5e15, respectively).

223 terval, 81%-95%) and specificity of 85% (95% confidence interval, 71%-93%).

224 is, positive predictive value was 93.3% (95% confidence interval, 77.6%-99.2%) by histopathologic val

225 for heart failure (hazard ratio, 11.40; 95% confidence interval, 8.38 to 15.50), followed by coronar

226 ions) demonstrated a sensitivity of 90% (95% confidence interval, 81%-95%) and specificity of 85% (95

227 nfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome.

228 by histopathologic validation and 96.2% (95% confidence interval, 86.3%-99.7%) by the combination of

229 s of therapy discontinuation were 49.9% (95% confidence interval, CI 43.6-56.5) for pembrolizumab, 58

230 ater BMI loss [mean adjusted difference (95% confidence interval, CI) -3.1 kg/m (-4.4 to -1.9) kg/m,

231 ll, odds of death from MI increased 34% (95% confidence interval: 0%, 80%) on days with heavy snowfal

232 /rehospitalizations (hazard ratio: 0.39; 95% confidence interval: 0.19 to 0.83; p = 0.01).

233 iting list (adjusted hazard ratio: 0.58; 95% confidence interval: 0.36-0.95; P = 0.03).

234 LDL-C was <70 mg/dl (hazard ratio: 0.61; 95% confidence interval: 0.40 to 0.91; p = 0.016), whereas C

235 % vs. 9.7%; adjusted hazard ratio: 0.61; 95% confidence interval: 0.53 to 0.71; p < 0.001).

236 an area under the curve (AUC) of 0.694 (95% Confidence Interval: 0.612-0.776) and classified correct

237 EA, quintile5 vs. 1 hazard ratio = 0.79, 95% confidence interval: 0.64, 0.98, and BH-adjusted Ptrend

238 vs. 11.2%; adjusted hazard ratio: 0.77; 95% confidence interval: 0.68 to 0.88; p < 0.001) and all-ca

239 NC, quintile5 vs. 1 hazard ratio = 0.81, 95% confidence interval: 0.71, 0.92, and BH-adjusted Ptrend

240 %) and 0.740 in the contemporary cohort (95% confidence interval: 0.723-0.758; sensitivity 81%, speci

241 decreased rate of PD (rate ratio = 0.83, 95% confidence interval: 0.75, 0.91) compared with no use.

242 diabetes of 0.766 in the primary cohort (95% confidence interval: 0.750-0.782; sensitivity 75%, speci

243 ce of AS-CA (area under the curve: 0.86; 95% confidence interval: 0.78 to 0.94; p < 0.001).

244 HF hospitalization (hazard ratio: 0.86; 95% confidence interval: 0.81 to 0.92; p < 0.001), with no s

245 operating characteristic curve of 0.89 (95% confidence interval: 0.82, 0.96) and an area under the p

246 ed hazard ratio: 0.91 per -5 mm Hg PASP; 95% confidence interval: 0.86 to 0.96; p = 0.0009).

247 RW-BMO values from all sectors was 0.95 (95% confidence interval: 0.86-1.00).

248 ompromised [4-year relative survival and 95% confidence interval: 0.87 (0.85-0.89), 0.87 (0.86-0.88),

249 ADHD in offspring (hazard ratio = 1.00, 95% confidence interval: 0.88, 1.14).

250 with DACLD (adjusted hazard ratio, 1.4; 95% confidence interval: 0.9, 1.9; P = .17).

251 nder the precision-recall curve of 0.96 (95% confidence interval: 0.93, 0.99).

252 between the 2 groups (odds ratio: 1.18; 95% confidence interval: 0.99 to 1.41; p = 0.26).

253 aged 30-49 years at enrollment to 1.13 (95% confidence interval: 1.02, 1.26) in those aged 70-89 yea

254 ratios per standard deviation were 1.10 (95% confidence interval: 1.05, 1.16) and 1.15 (1.10, 1.19) f

255 ompensation (adjusted hazard ratio, 3.7; 95% confidence interval: 1.1, 12.6; P = .04), but not for fu

256 y with age at BMI assessment, from 1.25 (95% confidence interval: 1.18, 1.33) in persons aged 30-49 y

257 io for each 10-ms decrease in EMW: 1.37; 95% confidence interval: 1.27 to 1.48; p < 0.0001).

258 equent MI or stroke (hazard ratio: 1.34; 95% confidence interval: 1.28 to 1.40) and major amputation

259 with DACLD (adjusted hazard ratio, 3.8; 95% confidence interval: 1.7, 9.5; P = .004).

260 with CACLD (adjusted hazard ratio, 7.4; 95% confidence interval: 2.7, 20.2; P < .001) and those with

261 At 1 year, RYGB patients had 28.4%TWL (95% confidence interval: 28.2, 28.5), SG 23.0%TWL (22.8, 23.

262 east square means difference: 3.9 mm(2); 95% confidence interval: 3.3 to 4.5; p < 0.0001).

263 irth weight was associated with 5.2 mum (95% confidence interval: 3.3-7.0) increase in RNFL thickness

264 ies resulted in a primary outcome (7.4%; 90% confidence interval: 3.4% to 15.9%).

265 occlusion for a score above 3 was 16.3 (95% confidence interval: 4.1 to 65.3; p < 0.0001).

266 l revascularization (hazard ratio: 8.13; 95% confidence interval: 7.96 to 8.29).

267 1.9%/year, with 10-year survival of 85% (95% confidence interval: 77% to 94%).

268 ion group (baseline-adjusted difference [95% confidence interval] -1.91 minutes [-5.53 to 1.70], p =

269 lysis, variables (subhazard ratio [SHR] [95% confidence interval]) associated with developing clinica

270 ed with clinical outcomes (hazard ratio [95% confidence interval], 4.8 [2.6-9.0], P < 0.01) when comp

271 Odds ratios (OR) with 95% confidence intervals (CI) for sarcopenia were higher for

272 Seroprevalence 95% confidence intervals (CI) were adjusted for assay sensit

273 ovided mean score differences (MDs) with 95% confidence intervals (CIs) for each HRQOL item and scale

274 stimated incidence rate ratios (RRs) and 95% confidence intervals (CIs) using Poisson regression, con

275 isks (RRs), standard mean differences of 95% confidence intervals (CIs) were calculated with the rand

276 Odds ratios (ORs) with 95% confidence intervals (CIs) were determined using logisti

277 tandardized incidence ratios (SIRs) with 95% confidence intervals (CIs).

278 timate summary relative risks (SRRs) and 95% confidence intervals (CIs).

279 er times for a 3-kilometer run (beta and 95% confidence intervals =4.93 (1.61, 8.25) and 4.65 (2.20,

280 obstructive CAD: for the PTP model, 72 (95% confidence intervals [CI]: 71 to 74); for the RF-CL mode

281 imated VI and blindness prevalence rates and confidence intervals for each survey measure and age gro

282 e population studies (odds ratio of 2.5, 95% confidence intervals of 1.4-4.4, P = 0.0013).

283 ferences or ratios (effect sizes) with their confidence intervals will be preferred.

284 ing the reporting odds ratios (ROR) with 95% confidence intervals.

285 DP were clearly attenuated, albeit with wide confidence intervals.

286 ls were used to estimate odds ratios and 95% confidence intervals.

287 dity of normative accounts, and suggest that confidence judgments might be based on point estimates o

288 lacebo group (difference, 3.5%; [90% 1-sided confidence limit for benefit, -0.9%]; P = .16; [97.5% 1-

289 for benefit, -0.9%]; P = .16; [97.5% 1-sided confidence limit for harm, 10.2%]; P = .84).

290 plementary ions and highlights these as high confidence matches between the two spectra.

291 patients possess the skills, knowledge, and confidence needed to effectively manage their health.

292 sets improve convergence and expand the high-confidence network synergistically.

293 esent between 2 and 30 per cent (90 per cent confidence) of the total population of merging binaries.

294 ng their respective regressors or asking for confidence ratings only in the second half of the experi

295 ds related to perceptual decision making and confidence report by either separating their respective

296 We found that confidence reports are best explained by the difference

297 We identified 2 high-confidence risk genes, each containing 2 DN damaging var

298 ve containment of transgenic microorganisms, confidence to a near-scientific certainty that they cann

299 We show Meltos has the ability to place high confidence validated SV calls on a refined tumor phyloge

300 In both Experiments, awareness and confidence were more diagnostic of the prospective decis